Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia by Mireille Crampe, Claire Andrews, Anne Fortune, Stephen E. Langabeer

“…The introduction of the tyrosine kinase inhibitor (TKI) imatinib has revolutionised the outlook of chronic myeloid leukemia (CML); however, a significant proportion of patients develop resistance through several mechanisms, of which acquisition of ABL1 kinase domain mutations is prevalent. …”
Get full text

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation by Håkon Reikvam, Jørn Skavland, Stein-Erik Gullaksen, Randi Hovland, Tobias Gedde-Dahl, Øystein Bruserud, Bjørn Tore Gjertsen

“…Allogeneic stem cell transplantation (allo-SCT) was considered the first-line treatment for CML, before the introduction of tyrosine kinase inhibitors (TKIs). However, patients are at risk for relapse years after transplantation. …”
Get full text

Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma by Jeannette C. Oosterwijk-Wakka, Liesbeth Houkes, Loes F.M. van der Zanden, Lambertus A.L.M. Kiemeney, Kerstin Junker, Anne Y Warren, Tim Eisen, Ulrich Jaehde, Marius T Radu, Rob Ruijtenbeek, Egbert Oosterwijk

“…Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). …”
Get full text

Experimental and Density Functional Theory Characteristics of Ibrutinib, a Bruton’s Kinase Inhibitor Approved for Leukemia Treatment by Ali I. Ismail

“…Ibrutinib, a Bruton’s tyrosine kinase that plays an essential role in the B-cell development and cancer cells, has been recently approved to treat chronic, lymphocytic, and other types of leukemia. …”
Get full text

Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease by Leslie B. Tolle

“…Patients with some fibrosing ILDs may respond well to immunosuppressants, but even patients who respond well to immunosuppressants initially may later show deterioration despite appropriate management. The tyrosine kinase inhibitor nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis, other chronic fibrosing ILDs with a progressive phenotype, and systemic sclerosis-associated ILD. …”
Get full text

Belzutifan for the treatment of renal cell carcinoma by Xiancheng Wu, David Lazris, Risa Wong, Scott S. Tykodi

“…Belzutifan has demonstrated activity in clinical trials as a front- and later-line therapy, and in combination with tyrosine kinase inhibitors. It has been largely well tolerated, although anemia represents a common on-target side effect and, along with hypoxia, requires monitoring during treatment. …”
Get full text

Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein by Pooja Gogia, Yiqing Xu

“…Therapy for ITP relies on competing and inhibiting the autoantibody binding and destruction (intravenous immunoglobulin and anti-D immunoglobulin and spleen tyrosine kinase (Syk) inhibitor fostamatinib), augmenting platelet production (thrombopoietin receptor agonists), immunosuppression to reduce the autoantibody production, as well as splenectomy. …”
Get full text

The Discovery of Novel Experimental Therapies for Inflammatory Arthritis by Charles J. Malemud

“…Over the past few years, sphingosine-1-phosphate, interleukin-7 receptor, spleen tyrosine kinase, extracellular signal-regulated kinase, mitogen-activated protein kinase 5/p38 kinase regulated/activated protein kinase, micro-RNAs, tumor necrosis factor-related apoptosis inducing ligand and the polyubiquitin-proteasome pathway were identified as promising novel targets for potential antiarthritis drug development. …”
Get full text

Fyn Signaling in Ischemia-Reperfusion Injury: Potential and Therapeutic Implications by Fang Du, Tao Tang, Qingzhu Li, Jiaxin Liu

“…Fyn is a nonreceptor tyrosine kinase belonging to the Src family of kinases (SFKs), which is related to many normal and pathological processes of the nervous system, including neurodevelopment and disease progression. …”
Get full text

Prospects of Antiangiogenic Therapy for Portal Hypertension in Liver Cirrhosis by D. V. Garbuzenko

“…It is shown that, so far, only tyrosine kinase inhibitors have been tested in patients with liver cirrhosis as an antiangiogenic therapy for portal hypertension. …”
Get full text

Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy by Karoline Mayer-Pickel, Sabine Horn, Uwe Lang, Mila Cervar-Zivkovic

“…An imbalance of angiogenic and antiangiogenic placental factors such as endoglin and soluble fms-like tyrosine kinase 1 has been implicated in the pathophysiology of preeclampsia. …”
Get full text

ERBB4 selectively amplifies TGF-β pro-metastatic responses by Peihong Luo, Huanyu Hong, Baoling Zhang, Jie Li, Shuyi Zhang, Chaomin Yue, Jin Cao, Jia Wang, Yuhan Dai, Qingqing Liao, Pinglong Xu, Bing Yang, Xia Liu, Xia Lin, Yi Yu, Xin-Hua Feng

“…Here, we report that ERBB4, a member of the ERBB receptor tyrosine kinase family, specifically promotes TGF-β′s metastatic response but not its anti-growth response. …”
Get full text

Rare skin adverse reactions induced by osimertinib: a case report and literature review by Ye Zhang, Mingzhu Ling, Min Wang, Ye Chen, Liting Zhang

“…Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in the treatment of EGFR mutation-positive advanced non-small cell lung cancer. …”
Get full text

Characterization of a pleomorphic rhabdomyosarcoma cell line by Sandra Stickler, Clemens Lang, Maximilian Rieche, Marie-Therese Eggerstorfer, Martin Hohenegger, Maximilian Hochmair, Gerhard Hamilton

“…Results of the novel functional BH1522 tests corroborate published tumor sequencing data that demonstrated alterations in receptor tyrosine kinase/MAPK, PI3K/AKT and mutated p53 as suspected drivers of malignant growth.…”
Get full text

Identification of C-Kit-Positive Interstitial Cells in the Dog Lower Urinary Tract and Relationship with Smooth Muscle and Nerves. Hypotheses for a Likely Pacemaker Role. by Silvana Arrighi, Giampaolo Bosi, Debora Groppetti, Fausto Cremonesi

“…Cryosections of normal canine bladder and urethra were immunofluorescently labelled with c-kit, a transmembrane, tyrosine kinase growth factor receptor, known to be expressed on the interstitial cells of Cajal (ICCs) of the gut. …”
Get full text

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment by Bassel Alsaed, Linh Lin, Jieun Son, Jiaqi Li, Johannes Smolander, Timothy Lopez, Pinar Ö. Eser, Atsuko Ogino, Chiara Ambrogio, Yoonji Eum, Tran Thai, Haiyun Wang, Eva Sutinen, Hilma Mutanen, Hanna Duàn, Nina Bobik, Kristian Borenius, William W. Feng, Behnam Nabet, Satu Mustjoki, Sanna Laaksonen, Benjamin K. Eschle, Michael J. Poitras, David Barbie, Ilkka Ilonen, Prafulla Gokhale, Pasi A. Jänne, Heidi M. Haikala

“…Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used to treat non-small cell lung cancers with EGFR mutations, but drug resistance often emerges. …”
Get full text

Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns by Maria Portelli, Byron Baron

“…The clinical presentation of PE and data gathered for the biochemical markers placental growth factor (PlGF), soluble Feline McDonough Sarcoma- (fms-) like tyrosine kinase-1 (sFlt-1), asymmetric dimethylarginine (ADMA), and methyl-lysine is being reviewed with the aim of providing both a clinical and biochemical understanding of how these biomarkers might assist in the diagnosis of PE or indicate its severity.…”
Get full text

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma by Masaud Shah, Muhammad Hussain, Hyun Goo Woo

“…While traditional approaches like surgical resection and tyrosine kinase inhibitors struggle against the tumor’s immune evasion, monoclonal antibody (mAb)-based immunotherapies have emerged as promising alternatives. …”
Get full text

Flt3/Flt3L Participates in the Process of Regulating Dendritic Cells and Regulatory T Cells in DSS-Induced Colitis by Jing-Wei Mao, Yu-Shuang Huang, Hai-Ying Tang, Jian Bi, Yan-Fei Liu, Ying-De Wang

“…Recent research showed that Fms-like tyrosine kinase 3 (Flt3) and Flt3 ligand (Flt3L) were involved in the process of DCs regulating T-regs. …”
Get full text

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms by Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B. Aragon-Ching

“…Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. …”
Get full text